CVS Health Sued Over Alleged Scheme to Siphon 340B Drug Program Savings

Why It Matters

If proven, the allegations could force CVS to return millions and trigger tighter oversight of 340B contracting, affecting how specialty pharmacies monetize drug discounts for safety‑net hospitals.

Key Takeaways

• Hospitals allege CVS kept $250 M of 340B savings.
• 340B program funds safety‑net hospitals’ uncompensated care.
• Claims suggest CVS used reduced reimbursements to hide profit spreads.
• Lawsuits could reshape specialty‑pharmacy contracting transparency.

Pulse Analysis

The 340B Drug Pricing Program, created by Congress in 1992, allows safety‑net hospitals to purchase outpatient drugs at steep discounts. In 2021, participants spent $43.9 billion on 340B drugs, with cancer therapies accounting for 41 percent of that spend. The program’s intent is to channel the resulting savings into uncompensated care, specialty services, and patient‑assistance initiatives for low‑income populations. As a financial lifeline for institutions operating on razor‑thin margins, any erosion of those funds can directly impact access to essential treatments for vulnerable patients.

The lawsuits filed by University of Michigan, University of Kansas, and Mount Sinai health systems allege that CVS Health’s specialty pharmacy and its PBM subsidiary, CaremarkPCS, manipulated reimbursement flows. Under the contracts, third‑party payments for 340B specialty drug claims were supposed to be passed to the hospitals after deducting only legitimate dispensing and administrative fees. Plaintiffs claim CVS delayed the identification of 340B‑eligible claims, then paid the hospitals a reduced amount while retaining the spread as profit. This alleged scheme not only contravenes contractual obligations but also undermines the statutory purpose of the 340B program, potentially diverting millions from indigent care.

Beyond the immediate $250 million at stake, the case raises broader questions about transparency and conflict of interest in integrated pharmacy‑benefit manager models. Regulators may intensify scrutiny of how PBMs, specialty pharmacies, and claims adjudication platforms interact, prompting tighter reporting requirements and possibly new legislation to safeguard 340B savings. For the industry, the outcome could reshape contract structures, enforce stricter audit mechanisms, and influence how hospitals negotiate with pharmacy networks, ultimately affecting the affordability of specialty drugs for the nation’s most vulnerable patients.